clinical trial · NCT06097962
Safety and Efficacy of NK510 to Treat NSCLC
Base Therapeutics (Shanghai) Co., Ltd.·early phase1·recruiting·n = 12
NSCLCNK510Tislelizumab，atezolizumab or sugemalimabNK510systemic therapy as selected by the investigator
brief summary
This study assesses the safety and efficacy of NK510 combined with PD-(L)1 inhibitors for relapsed/refractory advanced NSCLC, with two administration routes: intravenous infusion and intrapleural perfusion for malignant pleural effusion. Eligible patients need confirmed measurable lesions; intravenous cohort requires EGFR/ROS1/ALK negativity and disease progression after PD-(L)1 inhibitor treatment, while intrapleural cohort accepts targeted therapy-resistant patients with ≥500ml pleural effusion, and the treatment's safety, efficacy and immune microenvironment changes will be evaluated.
started
Jul 1, 2023
primary completion
Jul 1, 2026
completion
Jul 1, 2026
last updated
Mar 20, 2026
official title
Exploratory Study of NK510 Combined With PD-1 Blockade in the Treatment of Relapsed and Refractory Advanced NSCLC
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol